Skip to main content
. Author manuscript; available in PMC: 2013 Mar 15.
Published in final edited form as: Clin Cancer Res. 2011 Dec 21;18(6):1790–1797. doi: 10.1158/1078-0432.CCR-11-2361

Figure 3.

Figure 3

Response to EGFR-TKI therapy for the 6 patients with measurable disease. (A) Both patients receiving neoadjuvant TKI had a volumetric response (24), while 3 of 4 patients with advanced disease had a RECIST partial response. (B) CT imaging from one patient with advanced disease whose tumor demonstrated a marked response to erlotinib.